Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin Administration Routes in Post-CABG
NCT02474212Phase 4Completed
- Sponsor
- Tampere University Hospital
- Start
- May 2016
- Primary completion
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of enoxaparin in venous thromboembolism (VTE) and pulmonary embolism (PE) (4 arms), sponsored by Tampere University Hospital. Primary endpoint: Anti-Xa concentration maximum 0-24h. Started May 2016; status: completed.
02
Drugs
enoxaparin
03
Conditions
venous thromboembolism (VTE)pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT02474212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02474212.